Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors-Reference-Cited by-同舟云学术

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

Published:2021-01-20 Issue:3 Volume:10 Page:843-856
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Mascarenhas Leo¹^ORCID,Ogawa Chitose²,Laetsch Theodore W.³⁴^ORCID,Weigel Brenda J.⁵^ORCID,Bishop Michael W.⁶,Krystal Julie⁷^ORCID,Borinstein Scott C.⁸^ORCID,Slotkin Emily K.⁹^ORCID,Muscal Jodi A.¹⁰^ORCID,Hingorani Pooja¹¹^ORCID,Levy Donna E.¹²,Mo Gary¹³^ORCID,Shahir Ashwin¹⁴,Wright Jennifer¹⁴,DuBois Steven G.¹⁵¹⁶^ORCID

Affiliation:

1. Cancer and Blood Disease Institute Children's Hospital Los Angeles Norris Comprehensive Cancer Center Keck School of Medicine University of Southern California Los Angeles CA USA

2. Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan

3. Department of Pediatrics Harold C. Simmons Comprehensive Cancer Center UT Southwestern Medical Center Dallas TX USA

4. Pauline Allen Gill Center for Cancer and Blood Disorders Children's Health Dallas TX USA

5. Pediatric Hematology/Oncology University of Minnesota Masonic Cancer Center Minneapolis MN USA

6. Department of Oncology St. Jude Children's Research Hospital Memphis TN USA

7. Department of Pediatric Hematology/Oncology Cohen Children’s Medical Center New Hyde Park NY USA

8. Division of Pediatric Hematology/Oncology Vanderbilt University Medical Center Nashville TN USA

9. Memorial Sloan Kettering Cancer Center New York NY USA

10. Texas Children's Cancer Center Baylor College of Medicine Houston TX USA

11. The University of Texas MD Anderson Cancer Center Houston TX USA

12. Biostatistics and Biometrics Division Syneos Health Morrisville NC USA

13. PK/PD and Pharmacometrics Division Eli Lilly and Company Indianapolis IN USA

14. Oncology Division Eli Lilly and Company Indianapolis IN USA

15. Dana‐Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School Boston MA USA

16. Department of Pediatrics Harvard Medical School Boston MA USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3658

Reference28 articles.

1. Angiogenesis and vascular targeting in Ewing sarcoma

2. Distinct Effects of Ligand-Induced PDGFRα and PDGFRβ Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments

3. Inhibition of platelet‐derived growth factor‐mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571;McGary EC;Clin Cancer Res,2002

4. Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

5. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: A report from the children's oncology group

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japan’s contribution to an ongoing global pediatric cancer clinical trial: The experience of the National Cancer Center Hospital (NCCH) in Tokyo;EJC Paediatric Oncology;2024-06

2. What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?;Current Treatment Options in Oncology;2024-05-16

3. Survival and prognostic factors of pediatric brainstem gliomas: a single institution experience of 96 cases;2023-02-14

4. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review;International Journal of Biological Macromolecules;2022-03